AGENUS INC
No SEC Form 4 filings for $AGEN in the last 30 days.
See all $AGEN insider activity →Chardan Capital kept its Buy rating on Agenus with a $40 price target, implying a 378.5% upside from the Oct 2 close of $8.36. The firm cited durable patient outcomes and positive clinical signals in challenging subgroups for the BOT+BAL treatment.
Agenus reported 48% three-year overall survival in 35 patients from its Phase 1b ovarian cancer trial using botensilimab plus balstilimab. 25% of 44 treated patients were alive and off therapy at last follow-up. The results extend earlier Phase 1b signals, suggesting durability for the combination.
Chardan Capital initiated coverage of Agenus (AGEN) with a Buy rating and $40 price target, implying 454% upside from the Sep 17 close of $7.22. The firm highlights strong clinical data for Agenus's immunotherapy candidates, BOT and BAL, in treating MSS colorectal cancer, and the company's strategic focus on an unmet medical need.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning AGEN (AGENUS INC). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent AGEN coverage spans corporate actions, financial news and earnings.
Analyst upgrade and high price target may drive buying pressure.
Positive early‑stage data may lift Agenus shares as investors anticipate further trials and potential regulatory milestones.
Analyst upgrade and high price target may drive buying pressure.
Bullish call activity could support AGEN price.
Loan modification terms can change near-term liquidity, covenant headroom, and refinancing risk for Agenus.
AlphAI scores every news story that mentions AGEN with an AI model for sentiment and relevance, and aggregates insider trades from AGENUS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Chardan Capital kept its Buy rating on Agenus with a $40 price target, implying a 378.5% upside from the Oct 2 close of $8.36. The firm cited durable patient outcomes and positive clinical signals in challenging subgroups for the BOT+BAL treatment.
1 min readAgenus reported 48% three-year overall survival in 35 patients from its Phase 1b ovarian cancer trial using botensilimab plus balstilimab. 25% of 44 treated patients were alive and off therapy at last follow-up. The results extend earlier Phase 1b signals, suggesting durability for the combination.
1 min readChardan Capital initiated coverage of Agenus (AGEN) with a Buy rating and $40 price target, implying 454% upside from the Sep 17 close of $7.22. The firm highlights strong clinical data for Agenus's immunotherapy candidates, BOT and BAL, in treating MSS colorectal cancer, and the company's strategic focus on an unmet medical need.
1 min readBenzinga reports unusual options activity in 10 healthcare stocks. Notable trades include bullish calls on SELLAS Life Sciences (SLS) at $30 strike, bearish calls on Zoetis (ZTS) at $85 strike, and bullish puts on Lilly (LLY) at $1260 strike. Other stocks with notable activity include NBIX, AGEN, BBIO, BSX, NVO, and CAPR.
2 min readAgenus' unit has entered a second loan modification agreement with Ocean 1181, according to an SEC filing. The agreement is set to take effect on August 12, 2026.
1 min readAGENUS INC (AGEN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 12, 2026, Agenus West, LLC (the “Borrower”), a subsidiary of Agenus Inc. (the “Company”), and the Company, as guarantor, entered into a Second Loan Modification Agreement (the “Loan Modification Agreement”) with Ocea
4 min readAGENUS INC (AGEN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 10, 2026, the Compensation Committee (the "Committee") of the Board of Directors of Agenus Inc. (the "Company") a
2 min readAGENUS INC (AGEN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 5, 2026, the board of directors (the “Board”) of Agenus Inc., a Delaware corporation (the “Company”), increased t
2 min readAgenus (AGEN) shares fell about 7% after Q2 results. The company reported Q2 revenue of about $34.5m, while net income swung to a loss of about $0.6m and basic EPS returned to a small loss. Trailing twelve-month profit of $91.8m was driven by a one-off $110.3m gain, raising questions about earnings durability.
5 min readAGENUS INC (AGEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer • Previously announced oversubscribed $85 million private placement, with up to $255 million in potential proceeds from milestone-aligned
2 min read
